ARTICLE | Company News
Sheffield Medical Technologies Inc., Sequus deal
June 17, 1996 7:00 AM UTC
SEQU acquired an option to obtain an exclusive sublicense to develop and commercialize SHM's Liposome-CD4 technology as an AIDS therapeutic. SEQU will pay an upfront fee. SEQU has been funding work on the compound. ...